← Back to Search

Anti-bacterial agent

Vancomycin for Dialysis

Phase 1

Waitlist Available

Led By Jeffrey J Cies, PharmD, MPH

Research Sponsored by Drexel University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up until the end of the study, up to 33 months

Awards & highlights

Study Summary

This trial will also look at the safety of this method of vancomycin delivery in pediatric patients.

Eligible Conditions

Dialysis
Continuous Renal Replacement Therapy
Kidney Failure

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ until the end of the study, up to 33 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~until the end of the study, up to 33 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and until the end of the study, up to 33 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of patients with therapeutic vancomycin serum levels

Trial Design

1Treatment groups

Experimental Treatment

Group I: VancomycinExperimental Treatment1 Intervention

Patients with vancomycin mixed in the CRRT solution(s)

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Vancomycin

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Drexel UniversityLead Sponsor

150 Previous Clinical Trials

47,755 Total Patients Enrolled

The Center for Pediatric Pharmacotherapy, LLCUNKNOWN

Jeffrey J Cies, PharmD, MPHPrincipal InvestigatorDrexel University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Recent research and studies

clinicaltrials.govStudy

Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution

Jeffrey J. Cies,PharmD,MPH,BCPS-AQ ID,BCPPS,FCCP,FCCM,FPPAG 2017. "Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02663596.

~1 spots leftby Apr 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.